Document Classification

Section Type: METHODS

Text: A 12-week, multicenter, investigator-masked, randomized, parallel-group study was performed with more than 200 patients who were randomly assigned to regimens of tazarotene 0. 1 % gel alone, tazarotene plus a high-potency topical corticosteroid (fluocinonide 0. 05 % ointment, mometasone furoate 0. 1 % ointment, or diflorasone diacetate 0. 05 % ointment), or tazarotene plus a mid-high-potency topical corticosteroid (betamethasone dipropionate 0. 05 % cream, fluticasone propionate 0. 005 % ointment, or diflorasone diacetate 0. 05 % cream).